• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Efficacy of a plant-produced virus like particle vaccine in chickens challenged with Influenza A H6N2 virus

tetano

Editor, Senior Moderator
Plant Biotechnol J. 2019 Jul 27. doi: 10.1111/pbi.13219. [Epub ahead of print]
[h=1]Efficacy of a plant-produced virus like particle vaccine in chickens challenged with Influenza A H6N2 virus.[/h] Smith T[SUP]1,[/SUP][SUP]2[/SUP], O'Kennedy MM[SUP]1,[/SUP][SUP]2[/SUP], Wandrag DBR[SUP]1[/SUP], Adeyemi M[SUP]1[/SUP], Abolnik C[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The efficacy, safety, speed, scalability, and cost-effectiveness of producing hemagglutinin-based virus-like particle (VLP) vaccines in plants is well-established for human influenza, but untested for the massive poultry influenza vaccine market that remains dominated by traditional egg-grown oil-emulsion whole inactivated virus vaccines. For optimal efficacy, a vaccine should be closely antigenically matched to the field strain, requiring that influenza A vaccines be updated regularly. In this study, an H6 subtype VLP transiently expressed in Nicotiana benthamiana was formulated into a vaccine and evaluated for efficacy in chickens against challenge with a heterologous H6N2 virus. A single dose of the plant-produced H6 VLP vaccine elicited an immune response comparable to two doses of a commercial inactivated H6N2 vaccine, with mean hemagglutination inhibition titers of 9.3 log[SUB]2[/SUB] and 8.8 log[SUB]2[/SUB] , respectively. Compared to the non-vaccinated control, the H6 VLP vaccine significantly reduced the proportion of shedders and the magnitude of viral shedding by >100-fold in the oropharynx and >6-fold in the cloaca, and shortened oropharyngeal viral shedding by at least a week. Despite its potency, the cost of the antigenic mismatch between the inactivated H6N2 vaccine and challenge strain was evident not only in this vaccine's failure to reduce viral shedding compared to the non-vaccinated group, but its apparent exacerbation of oropharyngeal viral shedding until 21 days post challenge. We estimate that a kilogram of plant leaf material can produce H6 VLP vaccines sufficient for between 5,000 and 30,000 chickens, depending on the effective dose and whether one or two immunizations are administered. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] Nicotiana benthamiana ; Avian influenza; H6N2; VLP vaccine; chickens; viral shedding

PMID: 31350931 DOI: 10.1111/pbi.13219
Free full text
 
Back
Top Bottom